HRA004529
Title:
The latest edition of WHO and ELN guidance and a new risk model for Chinese acute myeloid leukemia patients
Release date:
2023-05-08
Description:
Diagnosis classification and risk stratification are of crucial in the survival prognostication and treatment selection of acute myeloid leukemia (AML). Here, we used a database of 536 AML patients to compare the 4th and 5th WHO, as well as the 2017 and 2022 version of ELN guidance.
Data Accessibility:   
Controlled access Request Data
BioProject:
Study type:
Disease Study
Disease name:
acute myeloid leukemia
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
DAC name:
DAC
Contact person:
he pengcheng
Email:
hepc@163.com
Description:
Diagnosis classification and risk stratification are of crucial in the survival prognostication and treatment selection of acute myeloid leukemia (AML). Here, we used a database of 536 AML patients to compare the 4th and 5th WHO, as well as the 2017 and 2022 version of ELN guidance.
Individuals & samples
Submitter:   he pengcheng / hepc@163.com
Organization:   The First Affiliated Hospital of Xi'an Jiaotong University
Submission date:   2023-05-04
Requests:   -